PROGRESSION FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS RECEIVING 3 TARGETED THERAPIES (TTS) FOR METASTATIC RENAL-CELL CARCINOMA (MRCC)

被引：0
|
作者：
Iacovelli, R. [1 ]
Santoni, M. [2 ]
Di Lorenzo, G. [3 ]
Cerbone, L. [4 ]
Aglietta, M. [5 ]
Masini, C. [6 ]
Giganti, M. O. [7 ]
Messina, C. [8 ]
Sternberg, C. N. [9 ]
Procopio, G. [10 ]
机构：
[1] Univ Roma La Sapienza, Dept Radiol Oncol & Human Pathol, Rome, Italy
[2] Univ Politecn Marche, Ancona, Italy
[3] Univ Federico II, Cattedra Oncol Med, Dept Oncol, Naples, Italy
[4] San Camillo & Forlanini Hosp, Rome, Italy
[5] Fdn Piemontese Ric Cancro Onlus, Div Oncol & Ematol, Candiolo, Italy
[6] Osped Policlin Modena, Dept Hematol Oncol, Modena, Italy
[7] Niguarda Ca Grande Hosp, Milan, Italy
[8] Osped Riuniti Bergamo, I-24100 Bergamo, Italy
[9] San Camillo Forlanini Hosp, Rome, Italy
[10] Ist Nazl Tumori, Fdn IRCCS, I-20133 Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：270 / 271
页数：2
相关论文
共 50 条
  • [31] Circulating tumor cells (CTC) predict progression free (PFS) and overall survival (OS) in patients with metastatic colorectal cancer
    Meropol, N. J.
    Cohen, S. J.
    Iannotti, N.
    Saidman, B. H.
    Sabbath, K. D.
    Miller, M. C.
    Doyle, G. V.
    Tissing, H.
    Terstappen, L. W. M. M.
    Punt, C. J. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [32] Race/Ethnicity and Survival in Metastatic Renal Cell Carcinoma: Outcomes for Patients Receiving First Line Targeted Therapies
    Dizman, Nazli
    Salgia, Nicholas J.
    Bergerot, Paulo G.
    Hsu, JoAnn
    Ruel, Nora
    Pal, Sumanta K.
    KIDNEY CANCER, 2020, 4 (03) : 159 - 166
  • [33] Prognostic ability of early tumor shrinkage on overall survival (OS) in metastatic renal cell carcinoma (mRCC) - a validation study
    Pond, G. R.
    Dietrich, M.
    Gruenwald, V.
    ANNALS OF ONCOLOGY, 2016, 27
  • [34] Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma
    Negrier, S.
    Bushmakin, A. G.
    Cappelleri, J. C.
    Korytowsky, B.
    Sandin, R.
    Charbonneau, C.
    Michaelson, M. D.
    Figlin, R. A.
    Motzer, R. J.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (10) : 1766 - 1771
  • [35] Association of percentage of tumor burden removed with debulking nephrectomy and progression-free survival (PFS) in metastatic renal cell carcinoma (mRCC) patients (Pts) treated with VEGF-targeted therapy
    Barbastefano, J.
    Garcia, J. A.
    Elson, P.
    Wood, L. S.
    Lane, B. S.
    Dreicer, R.
    Campbell, S.
    Rini, B. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [36] Early onset hypothyroidism as a predictor for progression-free survival (PFS) and overall survival (OS) benefit in patients with advanced renal cell carcinoma treated with first-line sunitinib
    Pinto, Alvaro
    Garrido, Maria
    Cruz, Patricia
    Lopez, David
    Zambrana, Francisco
    Aguayo, Cristina
    Fellu, Jaime
    Espinosa, Enrique
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [37] Time to surgery (TTS) in renal cell carcinoma (RCC): Predictors and association with overall survival (OS).
    Kommalapati, Anuhya
    Tella, Sri Harsha
    Tandra, Pavankumar
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [38] OVERALL SURVIVAL DATA WITH SEQUENTIAL TARGETED THERAPIES IN METASTATIC RENAL CELL CANCER
    Procopio, Giuseppe
    Verzoni, Elena
    Iacovelli, Roberto
    Guadalupi, Valentina
    Agustoni, Francesco
    Gelsomino, Francesco
    Colonna, Valentina
    Stagni, Silvia
    Salvioni, Roberto
    ANTICANCER RESEARCH, 2011, 31 (05) : 1831 - 1831
  • [39] Age as a determinant of overall survival (OS) and progression free survival (PFS) in patients with stage III lung carcinoma: A Cleveland Clinic experience.
    Seepana, Jyothirmai
    Mohapatra, Suryanarayan
    Khalid, Sidra
    Subramaniann, Subanandhini
    Spiro, Timothy Peter
    Daw, Hamed
    Haddad, Abdo S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [40] Prognostic factors for survival in patients with metastatic renal cell carcinoma (mRCC) treated with antiangiogenic therapies: Overall results of a large experience.
    Procopio, G.
    Verzoni, E.
    Iacovelli, R.
    Mattana, F.
    Guadalupi, V.
    Mariani, L.
    Stagni, S.
    Salvioni, R.
    Buzzoni, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345